AF9 Antibody

Rabbit Polyclonal

Antigen Affinity Purified

Catalog No. A300-596A

Lot No. A300-596A-1

Protein ID NP_004520.1

GeneID 4300

APPLICATIONS	WB, IP, IHC
SPECIES REACTIVITY	Human
AMOUNT	100 µl
CONCENTRATION	1000 µg/ml
STORAGE/SHELF LIFE	2 - 8° C / 1 year from date of receipt
PHYSICAL STATE	Liquid
BUFFER	Tris-citrate/phosphate buffer, pH 7 to 8 containing 0.09% Sodium Azide
ISOTYPE	IgG
ORIGIN	USA
PRODUCTION PROCEDURES	Antibody was affinity purified using an epitope specific to AF9 immobilized on solid support. The epitope recognized by A300-596A maps to a region between residues 250 and 300 of human ALL1 Fused Gene from Chromosome 9 Protein (MLLT3, Myeloid/Lymphoid or Mixed-Lineage Leukemia Translocate 3) using the numbering given in entry NP_004520.1 (GeneID 4300). Immunoglobulin concentration was determined by extinction coefficient: absorbance at 280 nm of 1.4 equals 1.0 mg of IgG.
APPLICATIONS	Centrifuge tube to remove product from lid. Optimal working dilutions should be determined experimentally by the investigator. Prepare working dilution immediately before use.

Western Blot	1:5,000 - 1:15,000
Immunoprecipitation	1 - 4 µg/mg lysate
Immunohistochemistry	1:500 - 1:2,000. Epitope retrieval with citrate buffer pH 6.0 is recommended for FFPE tissue sections.

APPLICATION NOTES	Western blot of immunoprecipitates performed using Normal Pig Serum (Cat. No. S100-020), Goat anti-Rabbit Light Chain HRP Conjugate (Cat. No. A120-113P) and 4-20% SDS-PAGE (link to IP-western blot protocol in Additional Info section below). Western blot of lysates performed using standard western blot reagents and 4-20% SDS-PAGE.
IHC HUMAN CONTROLS	Ovarian Carcinoma, Prostate Carcinoma
ADDITIONAL INFO	https://www.bethyl.com/product/A300-596A Use the link above to view SDS, a current list of citations, and other product specific information. IP-western blot protocol: https://www.bethyl.com/content/protocol_IP_WB

This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc.

Eric McIntush, PhD | Chief Scientific Officer

Date: June 21, 2019



Detection of human AF9 by western blot and immunoprecipitation. *Samples:* Whole cell lysate (5, 10 and 50 µg for WB; 1 mg for IP, 20% of IP loaded) from HeLa cells. *Antibodies:* Affinity purified rabbit anti-AF9 antibody BL2311 (Cat. No. A300-596A) used for WB at 0.1 µg/ml (A) and 1 µg/ml (B), and used for IP at 3 µg/mg lysate. AF9 was also immunoprecipitated using rabbit anti-AF9 antibodies BL2310 (Cat. No. A300-595A), BL2312 and BL2313 (Cat. No. A300-597A) at 3 µg/mg lysate. *Detection:* Chemiluminescence with exposure times of 30 seconds (A and B).



Detection of human AF9 by immunohistochemistry. *Sample:* FFPE section of human ovarian carcinoma. *Antibody:* Affinity purified rabbit anti-AF9 (Cat. No. A300-596A) used at a dilution of 1:1,000 (1µg/ml). *Detection:* DAB